Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **Envelope glycoprotein trimer of HIV-1** (commonly called "HIV-1 Env trimer") is a membrane-anchored homotrimeric complex composed of three gp120 and three gp41 subunits, derived from cleavage of the gp160 precursor[4][5][3]. Located on the surface of HIV-1 virions, the Env trimer mediates viral entry by first binding to the CD4 receptor and a co-receptor (CCR5 or CXCR4) on host cells, triggering conformational changes that drive the gp41-mediated fusion of the viral and host membranes[1][2][3][5]. Env is the only HIV-1 structure exposed to the host immune system and is the main target for neutralizing antibodies; its extreme sequence variability, extensive glycosylation, and conformational flexibility help the virus evade immune responses[3][6]. Because of these properties, the Env trimer is a major focus for vaccine and therapeutic development, as well as basic research into viral entry and immune evasion mechanisms[3][6][1].
Inhibition of viral membrane fusion; Blockade of CD4 or co-receptor binding
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envelope glycoprotein trimer of HIV-1 (HIV-1 Env trimer).